UK markets closed
NIKKEI 225
28,600.41 -204.44 (-0.71%) HANG SENG
26,132.03 +5.10 (+0.02%) CRUDE OIL
83.72 -0.04 (-0.05%) GOLD FUTURES
1,808.50 +12.20 (+0.68%) DOW
35,759.90 +82.88 (+0.23%) BTC-GBP
46,197.25 +2,161.12 (+4.91%)
Merck & Co., Inc. (MRK)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
81.63+0.47 (+0.59%)
As of 1:06PM EDT. Market open.
| Previous close | 81.15 |
| Open | 81.03 |
| Bid | 81.44 x 800 |
| Ask | 81.45 x 800 |
| Day's range | 79.95 - 81.63 |
| 52-week range | 68.44 - 84.56 |
| Volume | 4,113,171 |
| Avg. volume | 13,453,856 |
| Market cap | 206.623B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 37.17 |
| EPS (TTM) | 2.20 |
| Earnings date | 28 Oct 2021 |
| Forward dividend & yield | 2.60 (3.20%) |
| Ex-dividend date | 14 Sept 2021 |
| 1y target est | 93.83 |
- Zacks
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.
- Business Wire
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
KENILWORTH, N.J., October 25, 2021--Merck Announces Positive Top-Line Results from Phase 3 Trials for Once-Daily Oral Combination of Doravirine/Islatravir for Treatment HIV-1 Infection
- Business Wire
Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults
KENILWORTH, N.J. & MIAMI, October 25, 2021--Merck and Ridgeback Announce Rolling Review by European Medicines Agency for Molnupiravir, an Oral Antiviral Medicine, for the Treatment of COVID-19
© 2021 Verizon Media. All rights reserved.
